This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2010 Jun 28;170(12):1007-8.

doi: 10.1001/archinternmed.2010.168.

Cholesterol-lowering therapy for primary prevention: still much we don't know

PMID: 20585062
DOI: 10.1001/archinternmed.2010.168

Editorial

Cholesterol-lowering therapy for primary prevention: still much we don't know

Lee A Green. Arch Intern Med. 2010.

. 2010 Jun 28;170(12):1007-8.

doi: 10.1001/archinternmed.2010.168.

Author

PMID: 20585062
DOI: 10.1001/archinternmed.2010.168

No abstract available

PubMed Disclaimer

Comment in

Trials by independent expert bodies.
Breimer LH, Mikhailidis DP. Breimer LH, et al. Arch Intern Med. 2010 Dec 13;170(22):2042; author reply 2043-4. doi: 10.1001/archinternmed.2010.457. Arch Intern Med. 2010. PMID: 21149770 No abstract available.

Comment on

Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants.
Ray KK, Seshasai SR, Erqou S, Sever P, Jukema JW, Ford I, Sattar N. Ray KK, et al. Arch Intern Med. 2010 Jun 28;170(12):1024-31. doi: 10.1001/archinternmed.2010.182. Arch Intern Med. 2010. PMID: 20585067 Review.
Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy: a critical reappraisal.
de Lorgeril M, Salen P, Abramson J, Dodin S, Hamazaki T, Kostucki W, Okuyama H, Pavy B, Rabaeus M. de Lorgeril M, et al. Arch Intern Med. 2010 Jun 28;170(12):1032-6. doi: 10.1001/archinternmed.2010.184. Arch Intern Med. 2010. PMID: 20585068 Review.

Similar articles

Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy: a critical reappraisal.
de Lorgeril M, Salen P, Abramson J, Dodin S, Hamazaki T, Kostucki W, Okuyama H, Pavy B, Rabaeus M. de Lorgeril M, et al. Arch Intern Med. 2010 Jun 28;170(12):1032-6. doi: 10.1001/archinternmed.2010.184. Arch Intern Med. 2010. PMID: 20585068 Review.
[How far the rates of cholesterol have to be lowered in primary prevention?].
Rodondi N. Rodondi N. Rev Med Suisse. 2010 Mar 10;6(239):483-4. Rev Med Suisse. 2010. PMID: 20373693 French. No abstract available.
Update on statins and other lipid-lowering drugs.
Miller CA. Miller CA. Geriatr Nurs. 2001 Sep-Oct;22(5):276-7. doi: 10.1067/mgn.2001.119477. Geriatr Nurs. 2001. PMID: 11606910 No abstract available.
[Primary prevention of cardiovascular diseases by lowering lipids].
Klose G. Klose G. Internist (Berl). 1997 Jun;38(6):615-6. Internist (Berl). 1997. PMID: 9265009 German. No abstract available.
Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
Mora S, Ridker PM. Mora S, et al. Am J Cardiol. 2006 Jan 16;97(2A):33A-41A. doi: 10.1016/j.amjcard.2005.11.014. Epub 2005 Dec 1. Am J Cardiol. 2006. PMID: 16442935 Review.

See all similar articles

Cited by

Problems and possible solutions for therapy with statins.
Whayne TF Jr. Whayne TF Jr. Int J Angiol. 2013 Jun;22(2):75-82. doi: 10.1055/s-0033-1343358. Int J Angiol. 2013. PMID: 24436589 Free PMC article. Review.
Recent findings on the health effects of omega-3 fatty acids and statins, and their interactions: do statins inhibit omega-3?
de Lorgeril M, Salen P, Defaye P, Rabaeus M. de Lorgeril M, et al. BMC Med. 2013 Jan 4;11:5. doi: 10.1186/1741-7015-11-5. BMC Med. 2013. PMID: 23289647 Free PMC article.
Cost-effectiveness of the use of low- and high-potency statins in people at low cardiovascular risk.
Conly J, Clement F, Tonelli M, Hemmelgarn B, Klarenbach S, Lloyd A, McAlister FA, Husereau D, Wiebe N, Au F, Manns B; Alberta Kidney Disease Network. Conly J, et al. CMAJ. 2011 Nov 8;183(16):E1180-8. doi: 10.1503/cmaj.101281. Epub 2011 Oct 11. CMAJ. 2011. PMID: 21989469 Free PMC article.
Facts and ideas from anywhere.
Roberts WC. Roberts WC. Proc (Bayl Univ Med Cent). 2011 Jan;24(1):57-73. doi: 10.1080/08998280.2011.11928686. Proc (Bayl Univ Med Cent). 2011. PMID: 21307980 Free PMC article. No abstract available.
Are cardiovascular benefits in statin lipid effects dependent on baseline lipid levels?
Ferdinand KC. Ferdinand KC. Curr Atheroscler Rep. 2011 Feb;13(1):64-72. doi: 10.1007/s11883-010-0149-9. Curr Atheroscler Rep. 2011. PMID: 21104458 Review.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Medical
- MedlinePlus Health Information